SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Mar 26, 2025

Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: March 26, 2025 · CIK: 0001649989 · Accession: 0000000000-25-003266

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-285973

Date
March 26, 2025
Author
Division of
Form
UPLOAD
Company
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)

Letter

Re: Outlook Therapeutics, Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285973 Dear Lawrence Kenyon:

March 26, 2025

Lawrence Kenyon Chief Financial Officer and Interim Chief Executive Officer Outlook Therapeutics, Inc. 111 S. Wood Avenue, Unit #100 Iselin, NJ 08830

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Courtney M.W. Tygesson

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 26, 2025

Lawrence Kenyon
Chief Financial Officer and Interim Chief Executive Officer
Outlook Therapeutics, Inc.
111 S. Wood Avenue, Unit #100
Iselin, NJ 08830

 Re: Outlook Therapeutics, Inc.
 Registration Statement on Form S-3
 Filed March 20, 2025
 File No. 333-285973
Dear Lawrence Kenyon:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Courtney M.W. Tygesson
</TEXT>
</DOCUMENT>